WaveRx goes under after FDA-weary investors pull the plug
August 19, 2011 by MassDevice staff
WaveRx Inc., a stealthy medical device company, shutters its doors after investors grow tired of waiting on FDA approval for its diabetic neuropathy treatment.
WaveRx Inc.'s head slipped under the water forever, a victim of its backers' doubts about the FDA ever giving a green light to its technology for treating diabetic neuropathy.
Mark Wan, a founding partner at Three Arch Partners, told the VentureWire blog that his VC company and its two other partners in WaveRx, 5AM Ventures and Polaris Venture Partners, shut the taps last year after waiting for an answer from the FDA's Center for Devices & Biological Health about its proposal for a re-vamped clinical trial.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Is Valeant About To Make A Bold Bid For Bausch & Lomb?
- When regulators are ignored
- FDA Issues Draft Guidance to Help Companies Distinguish Between a Voluntary Medical Device Recall and a Product Enhancement
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
Navigation
NEWS
Uroplasty touts positive 3-year outcomes for neurostimulation in treatment of overactive bladder
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
FDA clears 21-inch medical monitors from NEC Display Solutions
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
Johnson and Johnson executive splits for the corner office at Itamar Medical | Personnel Moves
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J sues Shasta Technologies for logo infringement
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...
